Clinical Compound Library

• A unique collection of 3064 compounds in clinical trial phases for high throughput screening (HTS) and high content screening (HCS);
• All compounds have been permitted into clinical trial phases, categorized into Phase 1, Phase 2 and Phase 3.
• An effective tool for new drug screening and cell differentiation induction;
• Detailed compound information with structure, target, activity, IC50 value, and biological activity description;
• Structurally diverse, medicinally active, and cell permeable;
• NMR and HPLC validated to ensure high purity and quality;

High-Standard Entry Criteria

The TargetMol’s clinical compound library is established with strict entry criteria, ensuring that every compound in the library has a well-defined structure and high purity, verified through multiple analytical techniques such as NMR and HPLC/LC-MS. Through a multi-layered screening process, we exclude compounds with unclear structures, including mixtures and polymers.

Significant Strutural Diversity

The TargetMol’s clinical compound library possesses remarkable structural diversity, offering significant advantages in drug discovery. Using an 85% MACCS fingerprint similarity threshold, analysis of the library divides it into 3,038 categories, covering a wide chemical space. The library contains a vast array of compounds, ranging from simple to complex structures. This diversity provides extensive opportunities to identify lead compounds with high affinity and specificity for target proteins, greatly promoting drug innovation.
Whether targeting conventional drug targets or emerging, more challenging ones, the Clinical-Stage Small Molecule Drug Library offers a rich pool of candidate compounds, accelerating the drug development process.

Superior Drug-likeness

In the TargetMol’s clinical compound library, 66% of the compounds comply with Lipinski’s “Rule of Five” (Ro5), indicating that the library possesses favorable bioavailability and permeability. This library serves as an ideal starting point for drug development, and these properties help improve the success rate of drug discovery while accelerating research progress.

Multidimensional Pharmacokinetic Analysis

A multidimensional evaluation was conducted on the TargetMol Clinical-Stage Small Molecule Drug Library, systematically analyzing three key pharmacological parameters: blood–brain barrier (BBB) penetration, cardiac toxicity (hERG K+ channel blockade), and oral absorption properties.

Regular Updates to Compound Libraries

TargetMol ensures compound libraries stay at the forefront of science by regularly updating our database to include the latest approved and marketed drugs.

Flexible Packaging Options

TargetMol provides a variety of standard packaging sizes (such as 30 μL, 50 μL, 100 μL, 250 μL, and 1 mg), and offer customized packaging solutions tailored to specific needs.

Personalized Custom Services

TargetMol offers fully customized screening services, including the design and synthesis of compound libraries. Our highly flexible service is designed to efficiently meet the unique needs of scientists and researchers.

• Powder or pre-dissolved DMSO solutions in 96/384 well plate with optional 2D barcode
• Shipped with blue ice
• This compound library is provided at a concentration of 10 mM in DMSO. A small number of compounds may be provided in different solvents or concentrations due to solubility or stability requirements. Please refer to the specific product information for details.